The stock of BeOne Medicines Ltd ADR (ONC) has seen a 0.68% increase in the past week, with a 6.79% gain in the past month, and a 1.42% flourish in the past quarter. The volatility ratio for the week is 3.02%, and the volatility levels for the past 30 days are at 2.70% for ONC. The simple moving average for the last 20 days is -1.38% for ONC stock, with a simple moving average of 12.89% for the last 200 days.
Is It Worth Investing in BeOne Medicines Ltd ADR (NASDAQ: ONC) Right Now?
The 36-month beta value for ONC is at 0.31. Analysts have varying views on the stock, with 15 analysts rating it as a “buy,” 8 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ONC is 108.63M, and currently, shorts hold a 1.77% of that float. The average trading volume for ONC on June 27, 2025 was 443.69K shares.
ONC) stock’s latest price update
BeOne Medicines Ltd ADR (NASDAQ: ONC)’s stock price has decreased by -4.73 compared to its previous closing price of 267.12. However, the company has seen a 0.68% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-06-26 that SAN CARLOS, Calif.–(BUSINESS WIRE)—- $ONC #BeOne–In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today’s investor R&D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition. “At BeOne, our mission is simple yet bold: to create t.
Analysts’ Opinion of ONC
Many brokerage firms have already submitted their reports for ONC stocks, with RBC Capital Mkts repeating the rating for ONC by listing it as a “Outperform.” The predicted price for ONC in the upcoming period, according to RBC Capital Mkts is $312 based on the research report published on April 07, 2025 of the current year 2025.
BofA Securities, on the other hand, stated in their research note that they expect to see ONC reach a price target of $320, previously predicting the price at $207. The rating they have provided for ONC stocks is “Buy” according to the report published on March 03rd, 2025.
Morgan Stanley gave a rating of “Overweight” to ONC, setting the target price at $300 in the report published on December 03rd of the previous year.
ONC Trading at 2.99% from the 50-Day Moving Average
After a stumble in the market that brought ONC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.60% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ONC starting from Wang Lai, who sale 1,028 shares at the price of $260.00 back on Jun 23 ’25. After this action, Wang Lai now owns 0 shares of BeOne Medicines Ltd ADR, valued at $267,280 using the latest closing price.
Wu Xiaobin, the President and COO of BeOne Medicines Ltd ADR, sale 1,363 shares at $260.00 during a trade that took place back on Jun 23 ’25, which means that Wu Xiaobin is holding 0 shares at $354,380 based on the most recent closing price.
Stock Fundamentals for ONC
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.85 for the gross margin
The net margin for BeOne Medicines Ltd ADR stands at -0.09. The total capital return value is set at -0.08. Equity return is now at value -11.44, with -6.82 for asset returns.
Based on BeOne Medicines Ltd ADR (ONC), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21.
Currently, EBITDA for the company is -396.44 million with net debt to EBITDA at 12.96. When we switch over and look at the enterprise to sales, we see a ratio of 5.69. The receivables turnover for the company is 5.6for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.96.
Conclusion
In conclusion, BeOne Medicines Ltd ADR (ONC) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
